PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577510
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577510
Non-Insulin Diabetes Therapeutics
Global Non-Insulin Diabetes Therapeutics Market to Reach US$92.1 Billion by 2030
The global market for Non-Insulin Diabetes Therapeutics estimated at US$49.7 Billion in the year 2023, is expected to reach US$92.1 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. DPP4 Inhibitors, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$37.9 Billion by the end of the analysis period. Growth in the GLP-1 Receptor Agonists segment is estimated at 9.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$13.5 Billion While China is Forecast to Grow at 12.9% CAGR
The Non-Insulin Diabetes Therapeutics market in the U.S. is estimated at US$13.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$19.5 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.
Global Non-Insulin Diabetes Therapeutics Market - Key Trends & Drivers Summarized
Why Are Non-Insulin Diabetes Therapeutics Gaining Traction?
The global healthcare landscape is witnessing a rapid evolution in the treatment of diabetes, with a particular focus on non-insulin therapeutics. This surge in interest is rooted in the need for alternative treatments to insulin, which, despite its efficacy, presents several challenges for patients such as the need for regular injections, risk of hypoglycemia, and lifestyle disruptions. Non-insulin therapies, which include drugs like metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors, offer a more convenient and sometimes safer alternative for Type 2 diabetes patients. These drugs work by enhancing the body’s insulin sensitivity, reducing glucose production, and promoting the excretion of excess glucose. For millions of patients, these oral or injectable medications reduce the reliance on insulin injections, thus improving compliance and overall quality of life. Recent clinical trials have also shown that certain non-insulin therapies not only help control blood glucose levels but can also reduce cardiovascular risks, a significant concern for diabetic patients. As cardiovascular diseases are the leading cause of mortality in diabetic patients, this dual benefit has been a major factor in the increasing adoption of non-insulin therapeutics globally.
Furthermore, as the global prevalence of Type 2 diabetes continues to rise due to aging populations, urbanization, and lifestyle factors such as poor diet and lack of exercise, healthcare systems are under pressure to provide more cost-effective and scalable treatment options. Non-insulin therapies, being less invasive and more easily administered than insulin injections, represent a compelling solution in both developing and developed markets. Another reason these therapies are gaining traction is the growing recognition among healthcare professionals of the long-term benefits they offer in terms of patient quality of life. The convenience of oral tablets, as opposed to frequent injections, significantly improves patient adherence to treatment regimens, which is critical for the management of a chronic condition like diabetes. Moreover, non-insulin drugs often come with a lower risk of weight gain, another factor that has made them a preferred option for many patients and clinicians alike.
What Role Does Innovation Play In Shaping This Market?
Technological innovation is at the heart of the growing non-insulin diabetes therapeutics market. Pharmaceutical companies are increasingly focusing on the development of combination therapies that utilize multiple mechanisms to control blood sugar levels effectively. For example, a growing trend is the use of SGLT2 inhibitors in combination with GLP-1 receptor agonists, which targets glucose regulation from both ends—preventing glucose reabsorption by the kidneys while stimulating insulin production in the pancreas. This dual-action approach not only helps in better glucose control but also addresses multiple facets of Type 2 diabetes, such as weight management and cardiovascular risk. Another significant area of innovation is the formulation of extended-release medications that allow for less frequent dosing, which greatly improves patient compliance. Once-weekly injectables, like those in the GLP-1 class, have been particularly popular, offering patients more freedom and flexibility in managing their condition. This focus on patient-centric innovations has played a crucial role in driving the adoption of non-insulin therapies.
Furthermore, research is now pushing the boundaries beyond traditional mechanisms, exploring novel ways to target diabetes. One such frontier is the use of gut microbiome therapies, which aim to regulate blood glucose levels by altering the bacterial composition in the digestive tract. These therapies, still largely in clinical trials, offer the potential for non-invasive, long-term management of diabetes by leveraging the body's natural processes. Another exciting development is the exploration of gene-editing technologies, such as CRISPR, which could one day provide a permanent solution for diabetes by correcting the underlying genetic causes of insulin resistance or beta-cell dysfunction. As these innovations progress, they are expected to not only expand the range of therapeutic options available to patients but also revolutionize the way diabetes is treated. The ongoing integration of digital health tools, such as continuous glucose monitors (CGMs) that work in tandem with non-insulin therapies, is also creating a more connected, data-driven approach to diabetes management, enabling more personalized and precise treatment plans.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Non-Insulin Diabetes Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
III. MARKET ANALYSIS
IV. COMPETITION
